Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0ZM9M
|
||||
Former ID |
DNC002794
|
||||
Drug Name |
1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [551374] | ||
Structure |
Download2D MOL |
||||
Formula |
C15H15N3O
|
||||
Canonical SMILES |
C1=CC=C(C=C1)C(=O)CC2=CC=C(C=C2)N=C(N)N
|
||||
InChI |
1S/C15H15N3O/c16-15(17)18-13-8-6-11(7-9-13)10-14(19)12-4-2-1-3-5-12/h1-9H,10H2,(H4,16,17,18)
|
||||
InChIKey |
MERNPSIIBFTCAI-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Urokinase-type plasminogen activator | Target Info | Inhibitor | [551374] | |
NetPath Pathway | IL2 Signaling Pathway | ||||
EGFR1 Signaling Pathway | |||||
Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
E2F transcription factor network | |||||
Beta3 integrin cell surface interactions | |||||
Osteopontin-mediated events | |||||
Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
amb2 Integrin signaling | |||||
ATF-2 transcription factor network | |||||
AP-1 transcription factor network | |||||
Beta2 integrin cell surface interactions | |||||
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
FGF signaling pathway | |||||
Reactome | Dissolution of Fibrin Clot | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.